Skip to content

Menu

LexBlog, Inc. logo
CommunitySub-MenuPublishersChannelsProductsSub-MenuBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAboutContactResourcesSubscribeSupport
Join
Search
Close

UK committed to implementing EU Clinical Trials Regulation post-Brexit

By Jane Summerfield & Julia Fraser on April 30, 2018
Email this postTweet this postLike this postShare this post on LinkedIn

The UK Government has confirmed that it is committed to implementing the new EU Clinical Trials Regulation (EU) 534/2014 (“EU CTR”) into UK law post-Brexit.

The EU CTR entered into force in 2014 but will not apply until 6 months after the European Commission issues a notice confirming that the new EU clinical trials portal and database are fully functioning. The development of the portal and database is taking longer than anticipated and the date of application of the EU CTR is currently expected be March 2020. This means that, as drafted, the EU CTR will not be caught by the EU (Withdrawal) Bill (which will implement EU law into UK national law when the UK leaves the EU on 29 March 2019 as far as possible), leading to uncertainty as to the status of EU CTR in the UK.

During a recent debate in the House of Lords, the Government’s representative for life sciences, Baroness Goldie, confirmed that the Government is committed to implementing the EU CTR into UK law to the extent possible.

If, as currently expected, the date of application of the EU CTR occurs during the anticipated transition period (from 30 March 2019 until the end of 2020), the UK would be able to participate in the database and portal for the remainder of that period. However, Baroness Goldie acknowledged that participation in the database and portal beyond the transition period will require agreement with the EU as part of the wider Brexit negotiations.

The EU CTR harmonises the rules for conducting clinical trials throughout the EU and streamlines the application process. The new online EU clinical trial portal will enable sponsors of trials involving multiple sites to submit a single application to the authorities of all EU Member States concerned. Applications will initially be assessed by a single reporting EU Member State and then validated by the remaining concerned Member States and undergo national ethics reviews. The new procedure is expected to accelerate the authorisation procedure for conducting trials in the EU.

Consistent with the Government’s position, the UK Medicines and Healthcare products Agency’s (MHRA) recently published its Five Year Plan for 2018-2023, which refers to the MHRA’s progress in working towards implementation of the EU CTR as part of the UK’s strategy to continue to attract research following Brexit.

Photo of Jane Summerfield Jane Summerfield

Partner, London

Jane focuses on regulatory compliance and commercial agreements in the life sciences and food sectors. Jane advises on legal and regulatory requirements that apply during the product lifecycle, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences…

Partner, London

Jane focuses on regulatory compliance and commercial agreements in the life sciences and food sectors. Jane advises on legal and regulatory requirements that apply during the product lifecycle, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences, CE marking, product labelling, product composition, advertising and marketing activities, and pricing and reimbursement. Jane also advises on a wide range of commercial contractual arrangements, including consultancy, sponsorship, co-promotion, collaboration, manufacturing, distribution, services, quality and pharmacovigilance agreements, as well as helping clients to resolve issues with UK enforcement authorities and regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), Prescription Medicines Code of Practice Authority (PMCPA), Advertising Standards Authority (ASA), Food Standards Agency (FSA) and Trading Standards.
Jane combines commercial acumen with deep regulatory knowledge. She understands the business pressures faced by clients, having provided in-house regulatory compliance and commercial support to a major pharmaceutical client and a multinational food company. Jane provides “clear responses with business impact” Chambers UK.

Read more about Jane SummerfieldEmail
Show more Show less
  • Posted in:
    Administrative
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center

New to the Network

  • The FTI Award Journal
  • International Dispute Resolution
  • China Law Update Blog
  • Law of The Ledger
  • Antitrust Law Blog
Copyright © 2022, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo